Literature DB >> 25540748

Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.

Jun-Hui Du1, Xia Li2, Rong Li3, Lin Xu4, Ran-Ran Ma4, Song-Fang Liu5, Zhong Zhang6, Hong-Zhi Sun4.   

Abstract

AIM: To compare apelin-13, a ligand of G-protein-coupled receptor which has been shown to be involved in retinal angiogenesis, and vascular endothelial growth factor (VEGF) serum levels in type 2 diabetes mellitus (T2DM) with or without retinopathy, and to investigate the relationship between the serum concentration of apelin-13 and diabetes retinopathy.
METHODS: Sixty-nine patients with T2DM were enrolled. Of the 69 patients, 16 had proliferative diabetic retinopathy (PDR group), 23 had non-PDR (NPDR group) and 30 had no retinopathy (T2DM group). Subjects' information, including demographics, medical history, and use of medications were recorded. Their serum samples were collected for measuring the levels of C-reactive protein (CRP), serum lipid and glycosylated hemoglobin. Apelin-13 and VEGF serum levels were measured by enzyme-linked immunosorbent assay. Kruskal-Wallis test and one-way ANOVA were used to compare the differences among these groups. Chi-square test was used to assess categorical variables. Correlations between variables were investigated by Spearman rho correlation test and stepwise regression analysis. All statistical analyses were performed through SPSS 17.0 software.
RESULTS: Sex, age, body mass index (BMI), blood pressure, CRP, hemoglobin A1c (HbA1c) have no significantly difference in the three groups. Serum level of apelin-13 was significantly elevated in PDR group as compared with T2DM group (P=0.041). Differences of VEGF serum concentration in the three groups were statistically significant (P=0.007, P=0.007 and P<0.001, respectively). Spearman rho correlation test showed that serum apelin-13 was positively correlated with BMI, serum triglycerides, VEGF, but not with age, duration of diabetes, blood pressure, CRP, HbA1c and total-cholesterol. Stepwise regression analysis showed that BMI also significantly associated with serum apelin-13 (P=0.002), while VEGF and serum triglycerides were irrelevant.
CONCLUSION: This study elucidated a positive association of apelin-13 serum level with PDR, but not with VEGF. Apelin-13 may influence the promotion of PDR but unrelated with VEGF.

Entities:  

Keywords:  apelin-13; diabetic retinopathy; vascular endothelial growth factor

Year:  2014        PMID: 25540748      PMCID: PMC4270990          DOI: 10.3980/j.issn.2222-3959.2014.06.10

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  39 in total

1.  Is diabetic retinopathy an inflammatory disease?

Authors:  A P Adamis
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury.

Authors:  James C Simpkin; Derek M Yellon; Sean M Davidson; Shiang Y Lim; Abigail M Wynne; Christopher C T Smith
Journal:  Basic Res Cardiol       Date:  2007-08-13       Impact factor: 17.165

3.  Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

Authors:  Ahmed M Abu El-Asrar; Sofie Struyf; Dustan Kangave; Karel Geboes; Jo Van Damme
Journal:  Eur Cytokine Netw       Date:  2006-09       Impact factor: 2.737

Review 4.  Pro-inflammatory cytokines and adipose tissue.

Authors:  S W Coppack
Journal:  Proc Nutr Soc       Date:  2001-08       Impact factor: 6.297

5.  HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.

Authors:  Alexander J Glassford; Patrick Yue; Ahmad Y Sheikh; Hyung J Chun; Shirin Zarafshar; Denise A Chan; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-18       Impact factor: 4.310

6.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Keirnan L Willett; Oskar P Aspegren; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

7.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

Authors:  K Tatemoto; M Hosoya; Y Habata; R Fujii; T Kakegawa; M X Zou; Y Kawamata; S Fukusumi; S Hinuma; C Kitada; T Kurokawa; H Onda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

Review 8.  Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.

Authors:  Rafael Simó; Esther Carrasco; Marta García-Ramírez; Cristina Hernández
Journal:  Curr Diabetes Rev       Date:  2006-02

9.  Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus.

Authors:  Maria Gisella Cavallo; Federica Sentinelli; Ilaria Barchetta; Carmine Costantino; Michela Incani; Laura Perra; Danila Capoccia; Stefano Romeo; Efisio Cossu; Frida Leonetti; Luciano Agati; Marco G Baroni
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

Review 10.  An overview of the eye in diabetes.

Authors:  Anil Negi; Stephen A Vernon
Journal:  J R Soc Med       Date:  2003-06       Impact factor: 18.000

View more
  10 in total

Review 1.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

2.  Leptin activates the JAK/STAT pathway to promote angiogenesis in RF/6A cells in vitro.

Authors:  Le Zhang; Rong Li; Bing-Hui Wu; Ting-Ting Liang; Zhe Liu; Wei Ju; Yi Wang; Yu-Ting Wen; Ming-Cui Liu; Jun-Hui Du
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

3.  Low serum apelin levels are associated with mild cognitive impairment in Type 2 diabetic patients.

Authors:  Yongli Jiang; Shidi Wang; Xinghui Liu
Journal:  BMC Endocr Disord       Date:  2022-05-24       Impact factor: 3.263

Review 4.  Relationship between C-Reactive Protein Level and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.

Authors:  Jian Song; Song Chen; Xiaoting Liu; Hongtao Duan; Jiahui Kong; Zedong Li
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

5.  Apelin-13 Is an Early Promoter of Cytoskeleton and Tight Junction in Diabetic Macular Edema via PI-3K/Akt and MAPK/Erk Signaling Pathways.

Authors:  Yang Li; Yu-Jing Bai; Yan-Rong Jiang; Wen-Zhen Yu; Xuan Shi; Li Chen; Jing Feng; Gui-Bo Sun
Journal:  Biomed Res Int       Date:  2018-04-04       Impact factor: 3.411

Review 6.  Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.

Authors:  Hannah Youngblood; Rebekah Robinson; Ashok Sharma; Shruti Sharma
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

Review 7.  Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?

Authors:  Priyia Pusparajah; Learn-Han Lee; Khalid Abdul Kadir
Journal:  Front Physiol       Date:  2016-06-01       Impact factor: 4.566

8.  Influence of Apelin-13 on osteoporosis in Type-2 diabetes mellitus: A clinical study.

Authors:  Supin Liu; Wenlong Wang; Linlin Yin; Yitang Zhu
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

9.  VEGF, apelin and HO-1 in diabetic patients with retinopathy: a correlation analysis.

Authors:  Rensiqin Wu; Zhifeng Zhu; Dandan Zhou
Journal:  BMC Ophthalmol       Date:  2020-08-08       Impact factor: 2.209

Review 10.  The therapeutic potential of apelin in kidney disease.

Authors:  Fiona A Chapman; Duuamene Nyimanu; Janet J Maguire; Anthony P Davenport; David E Newby; Neeraj Dhaun
Journal:  Nat Rev Nephrol       Date:  2021-08-13       Impact factor: 28.314

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.